A Novel CXCL10-Based GPI-Anchored Fusion Protein as Adjuvant in NK-Based Tumor Therapy

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Muenchmeier, Niklas ^a   Boecker, Sophia ^a   Bankel, Lorenz ^b   Hinz, Laura ^a   Rieth, Nicole ^a   Lapa, Constantin ^a   Mendler, Anna N ^b   Noessner, Elfriede ^b   Mocikat, Ralph ^b   Nelson, Peter J ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOSYLPHOSPHATIDYLINOSITOL; HYBRID PROTEIN; MUCIN; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CELL MEMBRANE; CHO CELL; ENDOTHELIUM CELL; FAST PROTEIN LIQUID CHROMATOGRAPHY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL ADHESION; CELL LINE; CELL MEMBRANE; CHEMOKINE CXCL10; CHO CELLS; CRICETINAE; CRICETULUS; ENDOCYTOSIS; ENDOTHELIAL CELLS; FEMALE; GLYCOSYLPHOSPHATIDYLINOSITOLS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; MUCINS; NEOPLASM TRANSPLANTATION; NEOPLASMS; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; RHEOLOGY;

EID: 84883440444     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072749     Document Type: Article

References (44)

1. Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, et al. (2001) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 193: 661-670.
2. Fregni G, Perier A, Avril MF, Caignard A, (2012) NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies. Oncoimmunology 1: 38-47.
3. Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, et al. (2012) Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 1: 1323-1343.
4. Sconocchia G, Arriga R, Tornillo L, Terracciano L, Ferrone S, et al. (2012) Melanoma cells inhibit NK cell functions. Cancer Res 72: 5428-5429; author reply 5430.
5. Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, et al. (2012) Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 72: 1407-1415.
6. Tromp SC, Oude Egbrink MG, Dings RP, van Velzen S, Slaaf DW, et al. (2000) Tumor angiogenesis factors reduce leukocyte adhesion in vivo. Int Immunol 12: 671-676.
7. Dirkx AE, Oude Egbrink MG, Kuijpers MJ, van der Niet ST, Heijnen VV, et al. (2003) Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res 63: 2322-2329.
8. Griffioen AW, Damen CA, Mayo KH, Barendsz-Janson AF, Martinotti S, et al. (1999) Angiogenesis inhibitors overcome tumor induced endothelial cell anergy. Int J Cancer 80: 315-319.
9. Mukai S, Kjaergaard J, Shu S, Plautz GE, (1999) Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res 59: 5245-5249.
10. Pockaj BA, Sherry RM, Wei JP, Yannelli JR, Carter CS, et al. (1994) Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 73: 1731-1737.
11. Huang H, Liu Y, Xiang J, (2002) Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors. Cell Immunol 217: 12-22.
12. Griffioen AW, Damen CA, Blijham GH, Groenewegen G, (1996) Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 88: 667-673.
13. Griffioen AW, Damen CA, Martinotti S, Blijham GH, Groenewegen G, (1996) Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res 56: 1111-1117.
14. Wu NZ, Klitzman B, Dodge R, Dewhirst MW, (1992) Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Res 52: 4265-4268.
15. Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, et al. (2008) Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 14: 28-36.
16. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, et al. (1997) Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91: 521-530.
17. Haskell CA, Cleary MD, Charo IF, (1999) Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J Biol Chem 274: 10053-10058.
18. Fong AM, Erickson HP, Zachariah JP, Poon S, Schamberg NJ, et al. (2000) Ultrastructure and function of the fractalkine mucin domain in CX(3)C chemokine domain presentation. J Biol Chem 275: 3781-3786.
19. Medof ME, Nagarajan S, Tykocinski ML, (1996) Cell-surface engineering with GPI-anchored proteins. FASEB J 10: 574-586.
20. Milani V, Frankenberger B, Heinz O, Brandl A, Ruhland S, et al. (2005) Melanoma-associated antigen tyrosinase but not Melan-A/MART-1 expression and presentation dissociate during the heat shock response. Int Immunol 17: 257-268.
21. Lawrence MB, McIntire LV, Eskin SG, (1987) Effect of flow on polymorphonuclear leukocyte/endothelial cell adhesion. Blood 70: 1284-1290.
22. Gamble JR, Vadas MA, (1988) Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-beta. Science 242: 97-99.
23. Kukreti S, Konstantopoulos K, Smith CW, McIntire LV, (1997) Molecular mechanisms of monocyte adhesion to interleukin-1beta-stimulated endothelial cells under physiologic flow conditions. Blood 89: 4104-4111.
24. Grone HJ, Weber C, Weber KS, Grone EF, Rabelink T, et al. (1999) Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J 13: 1371-1383.
25. von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, et al. (2001) RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 103: 1772-1777.
26. Brenner CD, King S, Przewoznik M, Wolters I, Adam C, et al. (2010) Requirements for control of B-cell lymphoma by NK cells. Eur J Immunol 40: 494-504.
27. Sauty A, Colvin RA, Wagner L, Rochat S, Spertini F, et al. (2001) CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11). J Immunol 167: 7084-7093.
28. Clark-Lewis I, Mattioli I, Gong JH, Loetscher P, (2003) Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 278: 289-295.
29. Colvin RA, Campanella GS, Sun J, Luster AD, (2004) Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem 279: 30219-30227.
30. Colvin RA, Campanella GS, Manice LA, Luster AD, (2006) CXCR3 requires tyrosine sulfation for ligand binding and a second extracellular loop arginine residue for ligand-induced chemotaxis. Mol Cell Biol 26: 5838-5849.
31. Haraldsen G, Kvale D, Lien B, Farstad IN, Brandtzaeg P, (1996) Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human microvascular endothelial cells. J Immunol 156: 2558-2565.
32. Ranjbaran H, Wang Y, Manes TD, Yakimov AO, Akhtar S, et al. (2006) Heparin displaces interferon-gamma-inducible chemokines (IP-10, I-TAC, and Mig) sequestered in the vasculature and inhibits the transendothelial migration and arterial recruitment of T cells. Circulation 114: 1293-1300.
33. Manes TD, Pober JS, Kluger MS, (2006) Endothelial cell-T lymphocyte interactions: IP[corrected]-10 stimulates rapid transendothelial migration of human effort but not central memory CD4+ T cells. Requirements for shear stress and adhesion molecules. Transplantation 82: S9-14.
34. Peled A, Grabovsky V, Habler L, Sandbank J, Arenzana-Seisdedos F, et al. (1999) The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow. J Clin Invest 104: 1199-1211.
35. Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, et al. (2000) Burkitt lymphoma in the mouse. J Exp Med 192: 1183-1190.
36. Proudfoot AE, Power CA, Schwarz MK, (2010) Anti-chemokine small molecule drugs: a promising future? Expert Opin Investig Drugs 19: 345-355.
37. Smyth MJ, Hayakawa Y, Takeda K, Yagita H, (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2: 850-861.
38. Fruci D, Lo Monaco E, Cifaldi L, Locatelli F, Tremante E, et al. (2013) T and NK cells: two sides of tumor immunoevasion. J Transl Med 11: 30.
39. June CH, (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117: 1466-1476.
40. June CH, (2007) Principles of adoptive T cell cancer therapy. J Clin Invest 117: 1204-1212.
41. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, et al. (2010) Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 70: 6171-6180.
42. Kuschert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, et al. (1999) Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 38: 12959-12968.
43. Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, et al. (2003) Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci U S A 100: 1885-1890.
44. Stachel G, Trenkwalder T, Goetz F, El-Aouni C, Muenchmeier N, et al. (2013) SDF-1 fused to a fractalkine stalk and a GPI anchor enables functional neovascularization. Stem Cells. In press.